Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Glycol-split nonanticoagulant heparins are inhibitors of hepcidin expression in vitro and in vivo

Maura Poli, Michela Asperti, Annamaria Naggi, Natascia Campostrini, Domenico Girelli, Michela Corbella, Marina Benzi, Celine Besson-Fournier, Helene Coppin, Federica Maccarinelli, Dario Finazzi, Paolo Arosio

Blood (2014) 123 (10): 1564–1573.

https://doi.org/10.1182/blood-2013-07-515221

Published: 2014

Includes: Supplemental data

Journal Articles

Hepcidin Inhibition by Modified Heparins without Anticoagulant Activity

Maura Poli, Domenico Girelli, MD, Annamaria Naggi, Natascia Campostrini, PhD, Dario Finazzi, Federica Maccarinelli, Annalisa Castagna, Paolo Arosio, Ph.D.

Blood (2012) 120 (21): 483.

https://doi.org/10.1182/blood.V120.21.483.483

Published: 2012

Journal Articles

Anti-Heparanase Therapy in Combination with Conventional Chemotherapy Potently Inhibits Multiple Myeloma Growth in Vivo

Joseph P. Ritchie, Annamaria Naggi, Giangiacomo Torri, Benito Casu, Claudio Pisano, Paolo Carminati, Israel Vlodavsky, Ralph D. Sanderson, Yang Yang

Blood (2008) 112 (11): 5165.

https://doi.org/10.1182/blood.V112.11.5165.5165

Published: 2008

Journal Articles

The Heparanase Inhibitor SST0001 Is a Potent Inhibitor of Myeloma Growth In Vivo

Yang Yang, Joseph P. Ritchie, Telisha Swain, Annamaria Naggi, Giangiacomo Torri, Benito Casu, Claudio Pisano, Paolo Carminati, Israel Vlodavsky, Ralph D. Sanderson

Blood (2008) 112 (11): 246.

https://doi.org/10.1182/blood.V112.11.246.246

Published: 2008

Journal Articles

A Heparin-Based Inhibitor of Heparanase Blocks Myeloma Growth In Vivo by Targeting the Tumor Microenvironment.

Yang Yang, MD, PhD, Telisha Swain, BA, Annamaria Naggi, PhD, Giangiacomo Torri, PhD, Benito Casu, PhD, Israel Vlodavsky, PhD, Ralph D. Sanderson, PhD

Blood (2007) 110 (11): 1502.

https://doi.org/10.1182/blood.V110.11.1502.1502

Published: 2007

Journal Articles

The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy

Yang Yang, Veronica MacLeod, Yuemeng Dai, Yekaterina Khotskaya-Sample, Zachary Shriver, Ganesh Venkataraman, Ram Sasisekharan, Annamaria Naggi, Giangiacomo Torri, Benito Casu, Israel Vlodavsky, Larry J. Suva, Joshua Epstein, Shmuel Yaccoby, John D. Shaughnessy, Jr, Bart Barlogie, Ralph D. Sanderson

Blood (2007) 110 (6): 2041–2048.

https://doi.org/10.1182/blood-2007-04-082495

Published: 2007

NARROW

Glycol-split nonanticoagulant heparins are inhibitors of hepcidin expression in vitro and in vivo

Hepcidin Inhibition by Modified Heparins without Anticoagulant Activity

Anti-Heparanase Therapy in Combination with Conventional Chemotherapy Potently Inhibits Multiple Myeloma Growth in Vivo

The Heparanase Inhibitor SST0001 Is a Potent Inhibitor of Myeloma Growth In Vivo

A Heparin-Based Inhibitor of Heparanase Blocks Myeloma Growth In Vivo by Targeting the Tumor Microenvironment.

The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy

Email alerts

ASH Publications

American Society of Hematology

Glycol-split nonanticoagulant heparins are inhibitors of hepcidin expression in vitro and in vivo

Hepcidin Inhibition by Modified Heparins without Anticoagulant Activity

Anti-Heparanase Therapy in Combination with Conventional Chemotherapy Potently Inhibits Multiple Myeloma Growth in Vivo

The Heparanase Inhibitor SST0001 Is a Potent Inhibitor of Myeloma Growth In Vivo

A Heparin-Based Inhibitor of Heparanase Blocks Myeloma Growth In Vivo by Targeting the Tumor Microenvironment.

The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only